Serial change and its determinants of residual plaque characteristics under sirolimus-eluting stent: A coronary angioscopic study  by Kanai, Takashi et al.
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Objectives:  To examine  serial  change  in  the  residual  plaque  behind  the  sirolimus-eluting  stent  (SES)  using
coronary  angioscopy  in patients  with  SES  implantation  and  to  identify  its  baseline  determinants.
Background:  Previous  coronary  angioscopic  studies  have  demonstrated  that  SES  enhances  the yellow
grade  of  residual  plaque  during  follow-up  period.
Methods:  A  total  of  42  patients  with  stable  angina  pectoris  or silent  ischemic  heart  disease,  who  had  a
successful  SES  implantation  were  examined  by  coronary  angioscopy  both  at the  baseline  (SES  implan-
tation)  and the follow-up  period  (9–14  month  follow-up).  The  patients  were  divided  into  three  groups
as:  worsened  group  (WS:  yellow  color  grade  of coronary  plaque  at the  follow-up  period  was  worsened
compared  to the baseline  period,  n = 15),  no change  group  (NP:  no change  compared  to  the  baseline,
n  =  16),  and  improved  group  (IP:  improved  compared  to  the  baseline,  n =  11).  Then,  the  determinants  of
the nominal  change  of yellow  color  grade  were  examined  by multiple  regression  analysis.
Results:  The  low-density  lipoprotein  cholesterol  (LDL-C)  level  in IP group  at the  follow-up  was signiﬁcantly
decreased  compared  to  baseline  (from  120.0  ± 29.8  mg/dl  to 74.3  ±  16.7  mg/dl,  p  = 0.0005),  and  was  the
lowest  among  three  groups  (WS:  103.5  ±  16.4  mg/dl,  NC:  105.7  ±  18.7  mg/dl,  and IP:  74.3  ± 16.7  mg/dl).
Multiple  regression  analysis  revealed  that  family  history,  statin  administration,  baseline  serum  creatinine,
baseline  ‘in-stent’  thrombus,  and  follow-up  LDL-C  were  signiﬁcant  determinants  to  the  nominal  change
of yellow  color  grade  after  the  SES  implantation  (p <  0.0001).
Conclusions:  Serial  change  in  tissue  characteristics  within  residual  plaque  under  SES  is  determined  by
several  factors,  especially  LDL-C  level  as well  as  statin  administration.  Adequate  management  of  LDL-C
by statins  might  be  crucial  for stabilizing  residual  plaque  after SES  implantation.
Crown  Copyright  © 2012  Published  by  Elsevier  Ltd.  on  behalf  of Japanese  College  of  Cardiology.  Allntroduction
Drug-eluting stents such as sirolimus-eluting stent (SES) are
ell known to prevent the proliferation of smooth muscle cells;
owever, absent or poorly formed neointima appears to increase
he risk of stent thrombosis, especially when there is a yellow
laque under the stent [1].  More coronary yellow plaques have
een reported to be associated with a higher risk of stenosis pro-
ression within seven months [2]. Moreover, SES implantation
as been reported to increase the yellow color grade of residual
laque behind the struts [3],  which might be unfavorable. Previ-
us coronary angioscopic studies have demonstrated that lowering
∗ Corresponding author at: 30-1, O-yaguchi, Kamicho, Itabashi-ku, Tokyo 173-
610, Japan. Tel.: +81 3 3972 8111x2414; fax: +81 3 3972 1098.
E-mail address: kanai.takashi@nihon-u.ac.jp (T. Kanai).
914-5087/$ – see front matter. Crown Copyright © 2012 Published by Elsevier Ltd. on be
ttp://dx.doi.org/10.1016/j.jjcc.2012.06.002rights  reserved.
of low-density lipoprotein-cholesterol (LDL-C) with 3-hydroxy-
3-methylglutaryl-coenzymeA reductase inhibitor (statin) therapy
stabilizes yellow color grade of coronary plaques [4].  However,
the effect of statins on residual plaque under implanted SES is
unknown.
The purpose of the present study was to examine serial changes
in the residual plaque behind the SES using coronary angioscopy in
patients with SES implantation and to identify its baseline deter-
minants. The effect of statin on this change was also assessed.
Methods
Study designA  total of 42 patients who met  the following criteria were
enrolled in this retrospective observational study from January
2005 through December 2010 in Nihon University Hospital. The
half of Japanese College of Cardiology. All rights reserved.
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ntry criteria were as follows: (1) patients with stable angina pec-
oris or silent ischemic heart disease were enrolled; (2) SES were
uccessfully implanted on a new coronary lesion due to signiﬁcant
ngiographic stenosis without using any additional interventional
evices; (3) coronary angiography and angioscopy were performed
n the baseline period just after SES implantation as well as at the
ollow-up periods (9–14 months: an average of 11.2 ± 2.3 months
fter the implantation). The exclusion criteria were: (1) patients
ith acute coronary syndrome; (2) coronary arteries in which
esions were not suitable for angioscopic examination such as
eft main coronary artery; (3) patients with heart failure, uncon-
rolled hypertension, uncontrolled severe diabetes mellitus, liver
r kidney dysfunction, hemodialysis, or secondary dyslipidemia.
ll patients had provided written informed consent, and this study
as approved by the ethical committee at the Nihon University
ospital.
At baseline, coronary risk factors for each patient were identiﬁed
uch as smoking, hypertension, diabetes mellitus, hyperuremia,
yslipidemia, and family history. At baseline and follow-up, body
ass index (BMI), serum concentration of LDL-C, high-density
ipoprotein cholesterol (HDL-C), LDL-C/HDL-C ratio (L/H ratio),
erum creatinine (sCr), triglyceride, serum uremic acid, hemoglobin
1c (HbA1c), and high-sensitivity C-reactive protein (hsCRP) were
easured. The level of LDL-C was measured directly using a LDL-
 kit (Cholestest® LDL, Sekisui Medical Co. Ltd., Tokyo, Japan),
hich uses differences in afﬁnities of detergents to lipoproteins.
hen, management of LDL-C level and the control of other types
f coronary risk factor were undertaken following the Japan
therosclerosis Society (JAS) guidelines [5] for coronary artery dis-
ase. The type of statin used for each patient was determined by
he doctor who treated the patient. Some patients did not take
able 1a
atient characteristics.
Proﬁles 
All Worse (WS) No change (NC) 
N 42 15 16 
Age 66.7 ± 9.2 61.8 ± 8.0 70.0 ± 9.6 
Male  26 (61.9%) 9 (60.0%) 8 (50.0%) 
Smoking 21 (50.0%) 9 (60.0%) 7 (43.8%) 
Hypertension 32 (76.2%) 14 (93.3%) 12 (75.0%) 
Diabetes mellitus 19 (45.2%) 8 (53.3%) 7 (43.8%) 
Hyperuremia 5 (11.9%) 2 (13.3%) 1 (6.3%) 
Dyslipidemia 34 (81.0%) 13 (86.7%) 11 (68.8%) 
Family history 12 (28.6%) 7 (46.7%) 3 (18.8%) 
Patients coronary proﬁle
Target lesion LAD 23 (54.8%) 7 (46.7%) 10 (62.5%) 
LCX  8 (19.0%) 1 (66.7%) 4 (25.0%) 
RCA  11 (26.2%) 7 (46.7%) 3 (18.8%) 
Medicine proﬁle
Statin (%) 33 (78.6%) 11 (73.3%) 11 (68.9%) 
ARB 19 (45.2%) 8 (53.3%) 4 (25.0%) 
Ca  blocker 19 (45.2%) 8 (53.3%) 8 (50.0%) 
-Blocker 1 (2.4%) 0 (0.0%) 0 (0.0%) 
-Blocker 19 (45.2%) 8 (53.3%) 7 (43.8%) 
Allopurinol 4 (9.5%) 2 (13.3%) 1 (6.3%) 
Diuretics 3 (7.1%) 0 (0.0%) 2 (12.5%) 
Nitroglyceride 9 (21.4%) 3 (20.0%) 2 (12.5%) 
Nicorandil 27 (64.3%) 8 (53.3%) 10 (62.5%) 
Sulfonylurea 9 (21.4%) 3 (20.0%) 3 (18.8%) 
Pioglitazone hydrochloride 4 (9.5%) 1 (6.7%) 2 (12.5%) 
Warfarin 2 (4.8%) 1 (6.7%) 0 (0.0%) 
his table shows the clinical characteristics of all patients. Among the patients examine
hich  were worsened in 15 patients (WS  group), unchanged in 16 patients (NC group), a
ontinuous variables are expressed as mean ± SD. Comparisons of continuous variables 
SD  analysis. Comparisons of the categorical variables presented as numbers (percentage
S,  worsen group (yellow color grade of coronary plaque at the follow-up period was  wor
o  the baseline); IP, improved group (improved compared to the baseline); LAD, left ant
oronary artery; ARB, angiotensin receptor blocker.
* p < 0.05 was considered to signiﬁcant.logy 60 (2012) 270–276 271
statin because of side effects or decisions by the doctor during the
observation period.
Coronary angiography and percutaneous coronary intervention
All coronary angiograms and interventions were performed
in Nihon University Itabashi Hospital. Catheterization was per-
formed by the brachial or femoral artery approach, using a 6 or 7Fr
sheath and catheter. For the coronary segment with more than 75%
angiographic stenosis with ischemic symptoms of coronary artery
disease, SES implantation was  performed.
Angioscopic procedure and evaluation
A non-occlusion type of coronary angioscopic system (Machida
Endoscope Co. Ltd., Tokyo, Japan) was used in all patients. Before
the angioscopic observation, the white balance was adjusted for
color correction. Angioscopic studies were performed while the
blood was cleared away by the injection of 3% dextran-40, as previ-
ously reported [6].  During the observation, an experienced assistant
adjusted the light power to keep a regular degree of brightness on
the target plaque as well as to avoid excessive reﬂection. The angio-
scopic images were recorded by hard disk recorder. The yellow
color grade of targeted lesion was  evaluated after the stent implan-
tation in all patients of this study. The degree of yellowness of the
culprit plaques behind the stent was  graded as 0 (white), 1 (light
yellow), 2 (yellow), or 3 (intense yellow) as previously reported [6],
and the maximal yellow color grade of the coronary plaque behind
the stent was  determined, and regarded as the yellow color grade
in this study. The observer variability for assessing the yellow color
grade was already validated in the previous study [4,7]. This grade
p-Value
Improved (IP) Overall Tukey–Kramer
11 (ANOVA) WS vs. NC WS vs. IP NC vs. IP
68.6 ± 7.8 0.0286* 0.030* 0.1246 0.9137
9 (81.8%) 0.2424 – – –
5 (45.5%) 0.6247 – – –
6 (54.5%) 0.0712 – – –
4 (36.4%) 0.6836 – – –
2 (18.2%) 0.6280 – – –
10 (90.9%) 0.2767 – – –
2 (18.2%) 0.1538 – – –
6 (54.5%) – – –
3 (27.3%) 0.1943 – – –
2 (18.2%) – – –
11 (100%) 0.1249 – – –
7 (63.6%) 0.1030 – – –
2 (27.3%) 0.3723 – – –
1 (9.1%) 0.2361 – – –
4 (36.4%) 0.6836 – – –
1 (90.1%) 0.7969 – – –
1 (9.1%) 0.3850 – – –
4 (36.4%) 0.3274 – – –
9 (81.8%) 0.3200 – – –
3 (27.3%) 0.8566 – – –
1 (9.1%) 0.8569 – – –
1 (9.1%) 0.5029 – – –
d, the yellow grade of residual plaque behind SES was divided into three groups,
nd improved in 11 patients (IP group).
among three groups were performed using one-way ANOVA and Tukey–Kramer’s
) were performed by either the chi-square test or Fisher’s exact test.
sened compared to the baseline period); NC, no change group (no change compared
erior descending coronary artery; LCX, left circumﬂex coronary artery; RCA, right
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Table 1b
Patient characteristics and laboratory data proﬁle.
Proﬁles p-Value
Baseline Follow  up Baseline Follow-up Baseline  vs.  Follow-up
All WS NC  IP  All  WS  NC  IP  Overall  Tukey–Kramer  Overall  Tukey–Kramer  Overall  WS  NC  IP
N 42 15 16 11 42 15 16 11 (ANOVA) WS vs.  NC WS  vs.  IP  NC vs.  IP  (ANOVA)  WS  vs.  NC  WS  vs.  IP  NC  vs.  IP  (ANOVA)
Body  mass  index 23.2  ±  3.2 23.8  ±  2.9 22.1  ±  3.8 24.1  ±  2.4 23.9  ±  3.1 24.4  ±  3.2 22.8  ±  3.2 24.7  ±  2.8  0.2189  0.3246  0.9720  0.2736  0.2026  0.3234  0.9539  0.2446  0.0048** 0.0835  0.0783  0.2171
Laboratory data  proﬁle
LDL-C 114.3  ±  28.1 125.7  ±  27.1 100  ±  22.3  120.0  ±  29.8  96.2  ±  21.2  103.5  ±  16.4  105.7  ±  18.7  74.3  ±  16.7  0.0235* 0.0238* 0.8491  0.1327  <0.0001** 0.9367  0.0004** 0.0001** 0.0017** 0.0063** 0.3945  0.0005**
HDL-C 46.0  ±  12.0  43.0  ±  9.9  48.2  ±  15.4  46.7  ±  8.7  48.7  ±  11.6  43.0  ±  9.9  48.2  ±  15.4  49.4  ±  12.0  0.4813  0.4630  0.7188  0.9489  0.4661  0.4443  0.7228  0.9366  0.0345* 0.0970  0.0970  0.5049
L/H ratio  2.7  ±  1.0  3.1  ±  1.2  2.2  ±  0.6  2.7  ±  1.1  2.1  ±  0.6  3.1  ±  1.2  2.2  ±  0.6  1.6  ± 0.7  0.035* 0.0271* 0.5226  0.3686  0.008** 0.5727  0.0064** 0.0527  0.0003** 0.0042** 0.7421  0.0091**
Se rum  creatinine 0.78  ±  0.16 0.68  ±  0.11 0.81  ±  0.15 0.85  ±  0.18 0.84  ±  0.18 0.73  ±  0.14 0.90  ±  0.16 0.89  ±  0.19 0.0077** 0.0334* 0.0114* 0.7710  0.0119* 0.0172* 0.0455* 0.9903  <0.0001** 0.0079** 0.0015** 0.1944
Triglyceride
(mg/dl)
112.7 ±  54.0  124.0  ±  71.3  97.0  ±  41.1  120.2  ±  40.9  130.3  ±  70.6  124.0  ±  71.3  97.1  ±  41.1  121.6  ±  46.4  0.3401  0.3556  0.9826  0.5228  0.0205* 0.0169* 0.1827  0.6893  0.1631  0.1770  0.7085  0.9195
Uremic acid
(mg/dl)
5.3  ±  1.6  6.0  ±  1.7  4.5  ±  1.4  5.4  ±  1.5  5.5  ±  1.4  6.0  ±  1.7  4.5  ±  1.4  5.5  ± 1.4  0.0368* 0.0292* 0.5899  0.3271  0.7258  0.7065  0.9559  0.8981  0.1792  0.0748  0.0143* 0.6830
HbA1c (%) 6.4  ±  1.8  6.6  ±  2.0  6.3  ±  1.9  6.2  ±  1.4  6.0  ±  0.9  6.6  ±  2.0  6.3  ±  1.9  6.1  ± 0.8  0.7918  0.8711  0.7948  0.9790  0.6440  0.6626  0.9963  0.7565  0.0718  0.2369  0.1644  0.8662
hsCRP (mg/dl) 0.4  ±  0.5  0.3  ±  0.3  0.3  ±  0.3  0.6  ±  0.8  0.2  ±  0.2  0.3  ±  0.3  0.3  ±  0.3  0.1  ±  0.1  0.2510  0.9721  0.2625  0.3496  0.5701  0.9970  0.6392  0.5891  0.025* 0.2240  0.2751  0.0962
Patients coronary  proﬁle
Month  of  the
follow-up  periods
– –  –  –  11.2  ±  2.3  11.0  ±  2.1  11.3  ±  2.7  11.7  ±  2.3  –  – –  – 0.1074  0.5019  0.1891  0.4820  –  –  –  –
Maximum yellow
color  grade  of
target  coronary
1.6  ±  1.0  0.7  ±  0.8  1.9  ±  0.8  2.3  ±  0.9  1.7  ±  0.8  2.0  ±  0.7  1.9  ±  0.7  1.1  ± 0.8  <0.0001** 0.0006** <0.0001** 0.5521  0.007** 0.9329  0.0093** 0.0193* 0.4149  <0.0001** 0.3332  <0.0001**
Thrombus on  the
target  lesion
18(42.8%)  4(26.7%)  6(37.5%)  8(72.7%)  19(45.2%)  10(66.7%)  7(43.8%)  2(25.0%)  0.0116* –  –  – 0.1518* –  –  –  0.8129  0.0086** 1.0000  0.0041*
The clinical characteristics of all patients including the change in lipid proﬁle between the baseline and the follow-up period are shown.
The  average of maximal yellow color grade is described. The level of LDL-C and L/H ratio at the follow-up period were signiﬁcantly decreased compared to the baseline in WS  group and IP group. However, the level of LDL-C at
the  follow-up period was  signiﬁcantly lower in IP group compared to WS and NC group. The prevalence of ‘in-stent’ thrombus was decreased at follow-up period in IP group, whereas, increased in WS group.
Continuous variables are expressed as mean ± SD. Comparisons of continuous variables among three groups were performed using one-way ANOVA and Tukey–Kramer’s HSD analysis. Comparisons of continuous variables
between  two  groups were performed using paired/unpaired t-test or Wilcoxon’s signed rank test.
Comparisons of the categorical variables presented as numbers (percentage) were performed by either the chi-square test or Fisher’s exact test. WS,  worsening group (yellow color grade of coronary plaque at the follow-up
period  was  worsened compared to the baseline period); NC, no change group (no change compared to the baseline); IP, improved group (improved compared to the baseline); LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol; L/H ratio, ratio of LDL-C to HDL-C; HbA1c, hemoglobin A1c. hs-CRP, high-sensitivity C-reactive protein.
* p < 0.05 was  considered to signiﬁcant.
** p < 0.01 was  considered to signiﬁcant.
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Table  1c
Statin proﬁle.
Statins proﬁle (n = 42)
Atorvastatin 10 (23.8%)
Pitavastatin 9 (21.4%)
Rosuvastatin 8 (19.0%)
Fluvastatin 4 (9.5%)
Pravastatin 2 (4.8%)
No statins 9 (21.4%)
Statin(s): 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor(s). The
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Fig. 1. Changes in yellow color grades from the baseline to follow-up period for each
patient (n = 42). The change in yellow color grade for each patient was illustrated.
analyzed by simple/multiple regression analysis compared to
each baseline factor. Simple regression analysis reveals that age,
hypertension, family history, statin administration, baseline sCr,
Table 2
Angioscopic neointimal coverage at follow-up period.
WS (n = 15) NC (n = 16) IP (n = 11)
Grade 0 3 (20.0%) 0 (0.0%) 0 (0.0%)
Grade 1 6 (40.0%) 10 (62.5%) 3 (27.3%)
Grade 2 6 (40.0%) 6 (37.5%) 8 (72.7%)
Grade 3 0 (0.0%) 0 (0.0%) 0 (0.0%)
Average 1.2 ± 0.8 1.4 ± 0.5 1.7 ± 0.5.
p-Value overall p = 0.1011 (by ANOVA)
WS  vs. NC p = 0.7033 (by Tukey–Kramer’s HSD analysis)
WS  vs. IP p = 0.0853 (by Tukey–Kramer’s HSD analysis)
NC  vs. IP p = 0.3097 (by Tukey–Kramer’s HSD analysis)
The angioscopic degree of neointimal coverage of sirolimus-eluting stents at the
follow-up period for all group are shown in this table. No grade 3 of neointimalypes of statins used in the subjects of the present study are demonstrated. Most
atients (78.6%) were treated by statin and all of the patients in the improved group
ere having statin.
as determined at the most diseased portion (at the segment with
he maximum yellow grade). The neointimal coverage over the SES
t follow-up period was also graded as 0 (struts are exposed with-
ut any neointima), 1 (struts bulge into the lumen, although they
ere covered by thin neointima), 2 (struts are embedded by neoin-
ima but are seen translucently), 3 (struts are fully embedded and
nvisible) as previously reported [1] and the dominant degree of
eointimal coverage within an examined stent was used as an index
f neointimal coverage of stent of interest in this study.
Angioscopic evaluation was performed by two  experienced
eviewers who had no knowledge of the background data of the
atients. When the two reviewers’ grades were in disagreement, a
hird experienced reviewer determined the evaluation.
tatistical analysis
Continuous variables are presented as the mean ± SD. Com-
arisons of continuous variables between the two groups were
erformed by the 2-sample t test or Wilcoxon’s signed rank test,
nd those between the baseline and the follow-up by the paired
 tests or Wilcoxon’s signed rank test according to their distri-
utions. Comparisons among three groups were performed by
ne-way ANOVA and Tukey–Kramer’s HSD analysis. Comparisons
f the categorical variables presented as numbers (percentage)
ere performed by either the chi-square test or Fisher’s exact
est. The determinants for nominal changes of angioscopic yel-
ow color grade between the baseline and the follow-up period
ere analyzed by simple/multiple regression analysis. In the sim-
le regression analysis, we ﬁrst used 32 variables at baseline and 6
ariables at follow-up period as potential factors (Appendix). The
ariables showing correlation with the nominal change with p < 0.1
n simple regression analysis were included in the multiple regres-
ion analysis. A subgroup analysis was also performed according
o the LDL-C level following JAS guidelines (LDL < 100 mg/dl) and
o the medication proﬁle with/without statin. The level of statisti-
al signiﬁcance was determined at p < 0.05. For statistical software,
MP  9.0.0 (SAS Institute Inc., Cary, NC, USA) was  used in this study.
esults
The clinical characteristics of all patients including the change
n lipid proﬁle between the baseline and the follow-up period are
hown in Tables 1a and 1b.  The type of statin, concomitant drugs,
esions examined, and stent which were used in the subjects of
he present study are demonstrated in Tables 1a and 1c.  A total
f 51 SESs were implanted in 27 left anterior descending arterial
egments, 8 left circumﬂex arterial segments, and 16 right coronary
rterial segments. The size of SES had a range of 2.5–3.5 mm in
iameter, and 18–33 mm in length. The level of LDL-C, HDL-C, L/H
atio, sCr, triglyceride, uremic acid, HbA1c, and hsCRP is shown in
able 1b.
The change in the maximal yellow color grade behind SES
or each patient is described in Fig. 1. Among the patientsThe red line shows worsening group, yellow line shows no change group, and blue
line  shows improvement group. The dotted lines in each group indicate the studies
in  patients without having statin. Wilcoxon’s signed rank test was used for analysis.
examined, the yellow grade of residual plaque behind SES wors-
ened in 15 patients (WS  group: red line), were unchanged in 16
patients (NC group: yellow line), and improved in 11 patients (IP
group: blue line). The proﬁles of each group are demonstrated in
Tables 1a and 1b.  Most patients (78.6%) were treated by statin and
all of patients in IP group were having statin. The level of LDL-C
and L/H ratio at the follow-up period were signiﬁcantly decreased
compared to the baseline in the WS  group and IP group. However,
the level of LDL-C at the follow-up period was signiﬁcantly lower
in IP group compared to WS  and NC group (74.3 ± 16.7 mg/dl, vs.
103.5 ± 16.4 mg/dl and 105.7 ± 18.7 mg/dl). The sCr level at follow-
up period was  signiﬁcantly increased in WS  group and NC group
compared to the baseline. The prevalence of ‘in-stent’ thrombus
was decreased at follow-up period in IP group, whereas, increased
in WS  group. Table 2 shows the angioscopic degree of neointimal
coverage of SES at the follow-up period for all groups. No grade 3 of
neointimal coverage existed in any groups. There were no statistical
differences in the degree among the groups.
The nominal changes in angioscopic yellow color grade werecoverage existed in any groups. There were no statistical differences in the degree
among the groups. WS,  worsening group (yellow color grade of coronary plaque
at  the follow-up period was worsened compared to the baseline period); NC, no
change group (no change compared to the baseline); IP, improved group (improved
compared to the baseline).
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Table 3a
Simple regression analysis (nominal yellow color).
Independent factor Estimate p-Value
Patient background characterization
Age 0.0345298 0.0465*
Hypertension (presence: 1, no: 0) −0.31250 0.0541
Family history (presence: 1, no: 0) −0.7500 0.0134*
Medical administration
Statin administration (yes: 1, no: 0) 0.66667 0.0839
Baseline data
Baseline sCr 2.547424 0.0089**
Baseline ‘in-stent’ thrombus 0.27778 0.0016**
Follow-up data
Follow-up LDL-C −0.019304 0.0072**
Follow-up L/H ratio −0.595839 0.0234*
Follow-up triglyceride −0.003994 0.0781
Neointimal coverage 0.7710487 0.0016*
The nominal changes in angioscopic yellow color grade were analyzed by simple
multiple regression analysis compared to each baseline factor. Simple regres-
sion analysis reveals that age, hypertension, family history, statin administration,
baseline sCr, baseline ‘in-stent’ thrombus, follow-up LDL-C, follow-up L/H ratio,
follow-up triglyceride, and neointimal coverage were potential determinants for
nominal change of yellow color grade of residual plaque. sCr, serum creatinine;
LDL-C, low-density lipoprotein cholesterol; L/H ratio, ratio of low- to high-density
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Fig. 2. Comparison of nominal change of angioscopic yellow color grade. The nom-
inal changes of yellow color grade in each low-density lipoprotein cholesterol
(LDL-C) group of patients were compared. The yellow color grade only in low LDL-Cipoprotein cholesterol.
 p < 0.05, **p < 0.01 were considered to signiﬁcant.
aseline ‘in-stent’ thrombus, follow-up LDL-C, follow-up L/H ratio,
ollow-up triglyceride, and neointimal coverage were potential
eterminants for nominal change of yellow color grade of resid-
al plaque as shown in Table 3a.  The multiple regression analysis
dentiﬁed the presence of family history, statin administration, sCr
t the baseline, baseline ‘in-stent’ thrombus, and follow-up LDL-C as
he signiﬁcant factors to be associated with the nominal change in
ngioscopic yellow color grade (Table 3b). In these tables, when the
alue of estimate was plus, the corresponding independent variable
as considered to be an improving factor of yellow grade, whereas
inus value of estimate suggested that the independent variable
as considered to be a worsening factor.
To validate the feasibility of our data in the JAS guideline, the
ubjects were divided into three groups to compare each efﬁ-
acy for yellow grade of residual plaque behind SES as: (1) Low
DL-C group (n = 15): patients with a well-controlled level of LDL-
 (<100 mg/dl) by having statin; (2) High LDL-C group (n = 18):
atients with a level of high LDL-C (≥100 mg/dl) regardless of
aving statin; (3) No statin group (n = 9): patients without hav-
ng statin was pre-selected by physician because LDL-C level was
ontrolled (<100 mg/dl) or fairly controlled (around 100 mg/dl).
here was no signiﬁcant difference in the LDL-C level among the
hree LDL-C groups at the baseline (p = 0.0681; Low LDL-C group:
able 3b
ultiple regression analysis (nominal yellow color).
Independent factor Estimate (95% CI) p-Value
Family history −0.304986 (−0.551088 to −0.05510881) 0.0170*
Statin
administration
0.31576 (0.0894028–0.5421146) 0.008**
Baseline sCr 1.588237 (0.0586801–3.1177933) 0.0424*
Baseline ‘in-stent’
thrombus
0.413516 (0.2211823–0.644722) 0.0003**
Follow-up LDL-C −0.013051 (−0.02901 to −0.004924) 0.0075**
verall: R2 = 0.72871, p < 0.0001. The multiple regression analysis identiﬁed the
resence of family history, statin administration, sCr at the baseline, baseline ‘in-
tent’ thrombus, follow-up LDL-C as the signiﬁcant factors to be associated with the
ominal change of angioscopic yellow color grade. The multiple regression analysis
evealed satin administration and the presence of ‘in-stent’ thrombus at the base-
ine are storing improving factors of yellow grade. sCr, serum creatinine; LDL-C,
ow-density lipoprotein cholesterol.
 p < 0.05, **p < 0.01 were considered to signiﬁcant.group was  signiﬁcantly decreased compared to the other LDL-C groups. †  p < 0.05
is  signiﬁcant by Wilcoxon’s signed rank test. *p < 0.05, **p < 0.01 is signiﬁcant by
Tukey–Kramer’s HSD analysis.
118.6 ± 29.7 mg/dl, High LDL-C group: 120.3 ± 27.3 mg/dl, No statin
group: 95.3 ± 19.9 mg/dl). The angioscopic yellow color grade was
signiﬁcantly reduced at the follow-up period in the low LDL-C group
(p = 0.0292, 1.9 ± 1.1–1.3 ± 0.8) compared to the baseline. More-
over, there was  a signiﬁcant difference in yellow color grade at the
follow-up period between the low LDL-C group and the high LDL-
C group (p = 0.0186, 1.3 ± 0.8 vs. 2.0 ± 0.7). The nominal change in
yellow color grade during the follow-up period was signiﬁcantly
different among each LDL-C group as shown in Fig. 2. Only this
group provided an overall improvement in the yellow grade in its
average.
Discussion
It has been documented that SES implantation might enhance
the yellow color grade of residual plaque behind the struts [3].
However, its exact mechanism has not yet been elucidated. The
present study demonstrated the mechanism in part that family
history, baseline sCr, baseline in-stent thrombus, follow-up LDL-
C levels, and statin administration were signiﬁcant determinants
of nominal change in yellow color grade after the SES implanta-
tion. Among these factors, family history and the level of follow-up
LDL-C were worsening factors, whereas statin administration,
baseline sCr, and baseline in-stent thrombus were improving
factors.
It has been speculated that the increase in yellow grade which
can be frequently seen in the natural serial atherosclerotic process
may  correspond to the increase in content or size of lipid compo-
nent within plaque, or to the decrease in thickness of ﬁbrous cap,
and vice versa [7–9]. The worsening factors in this study, which
are family history and the level of follow-up LDL-C, are well known
to be among the strongest independent factors to determine the
relative risk of coronary events in the Japanese population [10].
Therefore, these data suggest that the increase in yellow grade of
residual plaque behind SES might have a potential common process
with the natural time-course of atherosclerosis.The present study also demonstrated that the angioscopic yel-
low color grade of coronary plaque behind SES was signiﬁcantly
decreased compared to the baseline in the low LDL-C group dur-
ing the 9–14 months after SES implantation. However, it was
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ot signiﬁcantly changed in the high LDL-C group in spite of
aving statin but less than in the no statin group. This result
ndicates the yellow color grade of coronary plaques at SES implan-
ation could be possibly stabilized if the LDL-C level is adequately
ontrolled by having statin. The adequate lowering of LDL-C by
aving statin might prevent the biochemical action to the resid-
al plaque of sirolimus to enhance the yellow grade of residual
laque.
Multiple regression analysis revealed that statin administra-
ion was a major improving factor of yellow grade of residual
laque behind SES. This effect may  come from not only an LDL-
 lowering effect but also some direct pleiotropic effect. Statin
apidly improves vascular endothelial function, attenuates vascular
nﬂammation, stabilizes plaques, corrects prothrombotic tenden-
ies, and inﬂuences myocardial protection and remodeling [4,11].
hese effects seemed to be related to LDL-C reduction or to a
ariety of LDL-C independent mechanisms. Previous studies have
hown that lipid-lowering therapy with statin decreased lipid con-
ent and inﬂammatory activity, and increased collagen content
8,12].  Moreover, Kawasaki et al. reported that yellow plaque color
as not dependent on the thickness of the lipid-core but on the
hickness of the ﬁbrous cap by intravascular ultrasound and angio-
copic observations [13]. Increased collagen content should make
hin ﬁbrous caps thicker. Therefore, increased collagen content
nd decreased lipid content of coronary plaques by statin ther-
py might be a major mechanism to reduce angioscopic yellow
rade.
Another important speculation might be regarding the
nhibitory effect of lipid-lowering or statin administration on SES
peciﬁc actions to the residual plaque. Inoue et al. have reported
edial smooth muscle cell depletion was present only in the
ortions where SES struts directly contacted the medial wall lay-
rs [14]. Nakazawa et al. suggested neoatherosclerotic change of
tented plaque [15]. Yamamoto et al. reported that SES likely causes
ersistence of yellow color behind the stent strut with a thin
eointimal coverage [16]. Finn et al. reported in an animal exper-
ment that SES implantation provokes eosinophilic/heterophilic
nﬁltration of the arterial wall [17]. On the other hand, arterial
acrophage inﬁltration was abolished by atorvastatin treatment
n an animal experimental study [18]. It has been hypothesized
hat the lipid pool acts as a reservoir and a secondary source of
he drug, thus resulting in increased drug efﬁcacy and an extended
rug-eluting time, because such a lipid pool favors hydropho-
ic drugs such as sirolimus [16,19]. The lipid-lowering by statin
educed the lipid content as the reservoir, furthermore, brought a
ecrease in inﬂammatory activity and increased collagen content
nd made the neointimal coverage of stent strut thicker. There-
ore, it might be possible that these effects explain the reduction in
ngioscopic yellow color grade of plaque behind SES in the present
tudy.
This study also indicated that the existence of ‘in-stent’ throm-
us within newly implanted SES stent at the baseline was one of the
ajor determinants of nominal change in yellow grade of residual
laque behind SES. It has been suggested that thrombus is seen in
he mid  process to repair the injury of vessel wall after the stent
xpansion [1,6]. In the present study, in-stent thrombus at follow-
p period could be more frequently observed, which might suggest
he delayed healing process from local inﬂammation. In addition
here was a tendency among the three groups for a reduction in
he level of hsCRP at the follow-up period (p = 0.025 by overall
NOVA). It was interesting that the level of baseline sCr was also
n independent factor to determine the nominal change of yellow
olor. However, the range of the sCr level among the subjects was
oo narrow to conclude the direct net effect of sCr on the nominal
hange of yellow grade. Therefore, further investigation would be
eeded.logy 60 (2012) 270–276 275
Study limitations
This study assessed a limited number of patients, since the
patients with sufﬁcient angioscopic images both at the baseline and
follow-up periods after SES implantation were enrolled. Second, the
evaluation of yellow plaque color grade was relatively subjective,
in which the assessment of yellow color grade is semiquantita-
tive. The yellow grade of the examined plaque in this study was
determined at the segment with the maximum yellow grade within
plaque. However, it was  technically difﬁcult to precisely follow the
color change of each subdivided segment within stented plaque.
Therefore, our data regarding the change in yellow color grade
corresponded to the change in the maximum yellow grade within
plaque. Third, it is possible that the yellowness of residual plaque
behind the stent might not exactly correspond to the yellowness of
native non-stented plaque, which has a thin ﬁbrous cap and a large
lipid core. Further pathological examination would be necessary to
validate our data. Lastly, the previous studies have reported that the
yellow neointima coverage of SES strut [20,21] was seen as a phe-
nomenon of some inﬂammatory change by the effect of sirolimus.
However, the angioscopic observation in this study was  performed
at 9–14 months after stent implantation so that the neointima cov-
erage was  relatively premature and thin. Therefore, the color of
the neointima itself was  difﬁcult to separately determine at that
period. Further long-term observation would be necessary to eval-
uate the neointimal coverage of SES in terms of the degree of
inﬂammation.
Clinical implications
This study showed that adequate management of LDL-C level
with statin might inhibit the increase in yellow grade of resid-
ual plaque after SES implantation. It has been considered that
the increase in the yellow grade is related to late in-stent
thrombosis or secondary provocation of acute coronary syn-
drome around the stented area [1,3]. Therefore, these data can
be applied to the clinical implications that adequate manage-
ment of LDL-C level with statin just after SES implantation might
have inherent favorable effects to prevent several SES-speciﬁc
complications.
Conclusions
Serial change of tissue characteristics within residual plaque
under SES was determined by several factors, especially LDL-C level
as well as statin administration. Adequate management of LDL-
C level by having statin might be crucial for stabilizing residual
plaque after SES implantation, which would reduce unfavorable
complications.
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The following 32 variables at baseline and 6 variables at follow-
p were considered as potential factors: baseline characteristics
age, gender, smoking, hypertension, diabetes mellitus, dyslipide-
ia, family history of CAD, BMI, month of follow-up period, target
esion of coronary artery, baseline angioscopic yellow color grade,
he existence of ‘in-stent’ thrombus), baseline blood parameters
LDL-C, HDL-C, L/H ratio, sCr, triglyceride, uremic acid, HbA1c,
sCRP), concomitant drugs (statin, angiotensin receptor blocker, Ca
locker, -blocker, -blocker, allopurinol, diuretics, nitroglyceride,
icorandil, sulfonylurea, pioglitazone hydrochloride, warfarin),
nd follow-up characteristics (follow-up angioscopic yellow color
rade, neo-intima coverage grade) and follow-up blood parameters
LDL-C, HDL-C, L/H ratio, triglyceride).
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